New hope for tough prostate cancer: drug combo trial launches

NCT ID NCT07047118

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 5 times

Summary

This Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works better than Pluvicto alone and to find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JSB462 (luxdegalutamide) and lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a Phase II trial with only 138 participants, so results are preliminary. The combination may not improve outcomes over Pluvicto alone and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC CANCER, CASTRATION-RESISTANT

Contacts and locations

Locations

City of Hope National Medical

Duarte, California, 91010, United States
Indiana University

Indianapolis, Indiana, 46202, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
NYU Laura and Isaac Perlmutter Cancer Center

New York, New York, 10016, United States
Novartis Investigative Site

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site

Adelaide, South Australia, 5000, Australia
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Linz, 4020, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Burnaby, British Columbia, V5G 4P3, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Olomouc, 779 00, Czechia
Novartis Investigative Site

Prague, 150 06, Czechia
Novartis Investigative Site

Brest, 29200, France
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Rostock, 18057, Germany
Novartis Investigative Site

Afula, 1834111, Israel
Novartis Investigative Site

Beersheba, 8457108, Israel
Novartis Investigative Site

Haifa, 3109601, Israel
Novartis Investigative Site

Jerusalem, 9103102, Israel
Novartis Investigative Site

Petah Tikva, 4941492, Israel
Novartis Investigative Site

Ramat Gan, 5265601, Israel
Novartis Investigative Site

Genova, GE, 16132, Italy
Novartis Investigative Site

Roma, RM, 00128, Italy
Novartis Investigative Site

Nijmegen, Gerlderland, 6532 SZ, Netherlands
Novartis Investigative Site

Hoofddorp, 2134 TM, Netherlands
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Granada, Andalusia, 18014, Spain
Novartis Investigative Site

El Palmar, Murcia, 30120, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Taipei, 103616, Taiwan
Providence Saint Johns Health Ctr

Santa Monica, California, 90404, United States
Rocky Mountain Cancer Centers

Denver, Colorado, 80218, United States
Univ of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, 15232, United States
Urology San Antonio

San Antonio, Texas, 78229, United States
XCancer Omaha LLC

Omaha, Nebraska, 68130, United States
Yale University School Of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.